| Application | Recommended Dilution |
|---|---|
| IHC | 1:50-1:200 |
Urokinase-type plasminogen activator (uPA/PLAU) serves as a critical serine protease in the plasminogen activation system, playing essential roles in extracellular matrix remodeling, cell migration, and tissue invasion. Beyond its well-characterized function in fibrinolysis, PLAU has emerged as a significant research target in cardiovascular biology and cancer progression, where its proteolytic activity influences tumor cell invasion and metastatic potential.
This recombinant monoclonal antibody, clone 10E5, offers researchers the reproducibility advantages inherent to recombinant technology. Because the antibody sequence is defined and expressed in a controlled system, you can expect consistent performance across experiments and between lot numbers, eliminating the variability that can complicate long-term studies or multi-site collaborations. The rabbit host origin combined with monoclonal specificity provides high-affinity binding to human PLAU, with the antibody raised against a synthetic peptide derived from the human protein sequence.
Validation testing confirms reliable performance in immunohistochemistry applications, with successful staining demonstrated in paraffin-embedded human prostate cancer tissue at 1:100 dilution using citrate buffer antigen retrieval. This validation in tumor tissue is particularly relevant given PLAU's established involvement in cancer biology. The antibody is also suitable for ELISA-based detection, with recommended IHC dilutions ranging from 1:50 to 1:200, giving you flexibility to optimize signal intensity for your specific tissue types and experimental conditions.
Supplied in a glycerol-containing buffer for stability, this affinity-purified antibody is well-suited for researchers investigating plasminogen activation pathways, cardiovascular disease mechanisms, or the role of proteolytic systems in tumor microenvironments.
Email: support@cusabio.com
Distributors Worldwide